%PDF-1.4
%
65 0 obj
<>
endobj
67 0 obj
<>stream
2019-07-03T13:48:57-05:00
QuarkXPress(R) 13.0
2024-03-28T04:12:42-07:00
2024-03-28T04:12:42-07:00
QuarkXPress(R) 13.0
application/pdf
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
%%DocumentProcessColors: Cyan Yellow Black
%%EndComments
uuid:efb826b3-1dd1-11b2-0a00-8c0827bd7700
uuid:efb826ce-1dd1-11b2-0a00-900000000000
endstream
endobj
14 0 obj
<>]>>
endobj
54 0 obj
<>
endobj
53 0 obj
<>
endobj
61 0 obj
<>
endobj
62 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
63 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
64 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0 0 585 783]/Type/Page/u2pMat[1 0 0 -1 0 783]/xb1 0/xb2 585/xt1 0/xt2 585/yb1 0/yb2 783/yt1 0/yt2 783>>
endobj
79 0 obj
[84 0 R]
endobj
80 0 obj
<>stream
HiOI%Cm"mh7]U]}pf!)hM6ql0xU^!d&P_2٨y:c劕]Su/c[*O`y
V)/+UZ1 qd)oofxR?2
]SY*b"`kIX8[[w(;ӒfB?sL$%-R[_7:IkMrd7Tϣ +
bikJ^HkQ<+7Y
YartdQi?qꧺN+^欨Ӳ,לaᄾ2VsE|Q{m'ËGn }G|wI)&x[e2-]xGTCTI""L#U ZN%g.>A1&膤zӍ'yNeYq2lXD$Ci8<1Ȋ-rO[a[S] h(kJHU~VT ]*{oM-qp
UBm%\w̳1bqvn{rM"olD.c~NQ+Q*Kv'?A ݿy;t}9v\N8*AHYuS(mk}VLƎ))ٰɅ!B C!Q]Ƿyl(jJVT|K[R Gu 2u3yc`IMG4{ܼ@ek2~\;v?Tw !2
X0־nzkGeֻ<)k#6ZJ³D*cv^"@inκslpl} m:YE\@|:63y3XgētxQ<խLԹY{:yiq_hO8y]#أMM3UѲoCo`?cOK;`CњpIe*RUv2X*+}Xiw0Nr2KEXv&̵Qmhq+M%I5ϵ8-xl(%ZmV&˗:?4E-1 phqXEZZ|5tNw×Y~m_~|<{SQSWj~x#0E=sV9Vؠr%Ϗs!Ffv!淪}l!gEؾ&xzJ/JGL%2bF/yzg*ag[[]"UKxܴ}/OwYhwNLL 65 >!ש%lpDvY?.*Ќ>&,I 8m"fڶ[%^WHJyӵmmL%<DTnkD҄ 83|C|\U(L#ǎ0BG-qasvXԂ3`ݒ@tJ1m-?@c`; Kk94p&0e}2=] yn1Y+hn-d_atj3Ŕ
P;`A\ק4I HxS VXklT$Fj:S 墹[:8qBlXQh
0I
N+;?A MKۛEe@c4%şTHRƥ3f=YZ$_OQۉEvL+e֑m]xYEemVkzHd̐v1>:kNbaMd~dY%SG-Z(XxnKQ((hawEZt0߬a]óc'[ٶEu^(r/ *CNέcCGeCGYst6.bU`,(/-*th ׄXq<
Sfh;kl4O wW .qmQnq
{,+q⧹&P.P"zcK;Bд?ƠSV:܋O˞w$G%w֢,ib
(Z D>l
t 4D1p糊gZj
endstream
endobj
27 0 obj
<>
endobj
18 0 obj
<>
endobj
49 0 obj
<>
endobj
23 0 obj
<>
endobj
73 0 obj
<>
endobj
19 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>stream
XU?o w`;K*KGMڥ@Y1o;;ԁ< 4#Nv'krgtdsӍzy?v f41uӶ&`xl|lFt#KSy;q8F0pABMc ?vܮ4Z<(ʥ*Mí.3gKŸeEX/V幫Z6;dX
jQ]|IU*d>UB:LYTzJD-߱u?ȉ~܌
endstream
endobj
20 0 obj
<>stream
XyTv2ݣ(j$QQT0b "II@*HÈ̊q]װuuz~yꮮz0fGg^>^!S=5ՔxZ!(Ae&>TqvjHjD/!?σ1Ej=L4s~H5jD#FfX`t藲 Ul5_QT((OUj1cr\ /Y
lܸqgYY??ҍRIU7@e8M/;_e5esőFX*IǡǏQWo\QC01037.9)[3`z֖qc #YD0#X
{8M/ǝp©y<,Hhd')-A-FX :
&+L7a,g̠Mb
JS9Xc,n`+ݓ<аR+ȲR%8P|r8|)%.~qP..Y2>R]Z&xrOKڻ-_4J,{;'p'.-t\"'+:k뛤W>1*.0yy?ridq4_JljQ[hK+??ӿ)[ˠ
qmДվdԲTFuF!lf7ӽwέx9Za>S_PͅGdDeNX+`+Pޫߌ2R',ɢ?T2?4qDR3Eݑ:tM_RMX,2܉(a&,E|X*g-A+"G'%|Ґ@e:6§UjtK{{Ot߿y)ZŧMLuqyEuz
"V.q_(|xv;װֻbTKB$N5EspN!O|{^n&k\ď=x34DRH72D(1ه1UEQRq79ኾW£NGt et/Yn.፝!4dq߂Eq8CPkƢ?5$C[F
/)( $`~^)Ӯ%B-WþTEmG}w_TùT>iˊc lna5B廎B?
B͜)8]=xYst8E=~]8f9^zYq
\
KF8)2be5솤IUVQg$aܺm!K8f<9{XŖ(F3932fqa<BuJמJR'oіrEuZ#I(gaGwoZq=:wTd8ҙˢGPEX r+ϸ>(RUs:NoϠtW&(XBs~>e0+B6*aWIjflV^ /&T}t09$pЋʃH[q{ZSisے&NOVƸ{:IT?t*w7np
>N}̖%ԀB7'ߚƁ!(>)RקPc38K#ab
M̃a
L{ga3#OܭQ Uy1Sad]mWa!6 piwp
vY-8Y?Q89+B0;Z$C-M5X0k9a0Ϳ~Ly8'
uݿwt\
l{x'1}u)4^(8Շ }iW'[髇os!#WuW\8/t578XA _YoB$G
}yRHbmޡׁR̉ζƚ3g*ϐ1^Q~d,plJ8Y1+qBg,"VUP3:olXA&9(RP2u(7繥l%aLq]cxc%>#8&Kٜ'TL'dJ|FO}L\%-P2?(c))dpUhČo+ˎ1zՆZqr
rZ58I(\br}a6gxQRixU
4wvY$M37'EKPoz؇k WvJ\*o10_mʏRf%
%9y)y՜of4ۺt;?C4: Gfs"7/߽}}-b>XtY*bOj
~KYX
W6ʳ-\MAIcH:٭)8S)\Һe>J B0s$J%t@ʮtMEWɀZn0':ZN5wWt`H<ԸAUxNKZú;Η
S#6aAk=`#ڭ85!bubL<9XW\ՔWH%"#RA$F(}ﱜ̖ĦF#K(+IP4pZc*+sAgӸު=Y$%{lCWʴμ*R/i*~Xi3v^1vHzUEFyJCly{rNҔӳ۾o/|{efSvK](`
OV>8L\c\]Le`2"{ˢ
@$D`kNщZh<'"njs;y=Oؓ}2F!
q$]M=#y~N{"Nk٤+};eK¢P-\A_?KX\W,ob5s+G飈wJ
pq4i-E~dRj~)RWE1a 3.ч$#wd/;J*cP.pGat\gԅ0^
vqz:~l%3`
K"gfĉ/=N1C*J.sHR_Jdt2ɏ呕`0@PsHgҦװ'pGK_gwmi-jOXN:a2%Բhm>DNL*W>Ơh v~0QխŁq24`qw8^q.nϙ%J̇v{Ndu2["s')L1 Y\3phCx<٢+t'={J8ba҆H>).zw f~p;%+̅ o[o.%\OywGL!W | XX8>VK/d;-+#nK2.z8M)j8aТVymf_?F]9ďfhCoz}/r#wa+t?~|ݓ55`؍kVBpxJ , Қ{4>*4W3Ӷsg#E>;+>bJ(SSqCP蟪xtVzpOn4lca_u!dH1es[%B s+L~ -γ8DϬ,Aa~l`RNK_o.ԣ0D1j[S<#* D%ƌ@ipn]8L0bqDK5@~ߠqi5TLPԜo:Q'+k),Δ-HXBEK>7^ԗ&^/&UǴe\]=!̙]^(U'@YZwn=iUՋ5ZOeBy_bBO
2.*I'?OI;
$i0nXƞ{JHWO=
yt^Ӥ&g׳ ̄+ۀhyhϹǍME